Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Pediatr. Jun 9, 2026; 15(2): 118421
Published online Jun 9, 2026. doi: 10.5409/wjcp.v15.i2.118421
Published online Jun 9, 2026. doi: 10.5409/wjcp.v15.i2.118421
Study on intravenous immunoglobulin use in a pediatric intensive care unit of a tertiary care center
Poovazhagi Varadarajan, Seenivasan Subramani, Vasanth Jeyaram, Lakshmi S Velmurugan, Raghul Jayaseelan, Gomathy Srividya Venugopal, Department of Pediatric Intensive Care, Institute of Child Health and Hospital for Children, Madras Medical College, Chennai 600008, Tamil Nādu, India
Author contributions: Varadarajan P, Subramani S, Jeyaram V contributed to the study conception and design; Velmurugan LS, Jayaseelan R and Venugopal GS performed material preparation, data collection, and data analysis; Varadarajan P, Subramani S wrote the manuscript draft and its revisions, with all authors providing feedback on all versions; and all the authors approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Madras Medical College, Institutional Review Board (Approval No. 04032025).
Informed consent statement: Consent from parents/care givers was waived by ethics committee as it was data collection from the patient file registry system of the unit.
Conflict-of-interest statement: We have no financial relationships to disclose.
STROBE statement: The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.
Data sharing statement: No additional data are available.
Corresponding author: Seenivasan Subramani, DM, Assistant Professor, Consultant, Department of Pediatric Intensive Care, Institute of Child Health and Hospital for Children, Madras Medical College, Tamil Salai, Egmore, Chennai 600008, Tamil Nādu, India.
Received: January 7, 2026
Revised: January 29, 2026
Accepted: February 13, 2026
Published online: June 9, 2026
Processing time: 128 Days and 1.6 Hours
Revised: January 29, 2026
Accepted: February 13, 2026
Published online: June 9, 2026
Processing time: 128 Days and 1.6 Hours
Core Tip
Core Tip: This study evaluates intravenous immunoglobulin (IVIG) use in a pediatric intensive care unit, highlighting indications, dosing, evidence support, and outcomes. The commonest indication was immunological diseases followed by neurological illness, infections, hematological diseases and cardiac diseases. Strength of recommendation varies in different diseases. Off label use was seen in about one -fifth of patients. Adverse effects were minimal. Evidence is lacking regarding the use of IVIG in many diseases. The study suggests multicentric trials to define proper indications of IVIG.